Colonic delivery of nicotine to treat inflammatory bowel disease
AssigneeMayo Foundation for Medical Education and Research
InventorsWilliam Sandborn, John Rhodes, Peter Rhodes, Brian Kenneth Evans
Life of this patent
Estimating the term…
Abstract
A method is provided to treat inflammatory bowel disease by locally administering to the colon an effective amount of nicotine or a pharmaceutically acceptable salt thereof, preferably via formulations adapted for delayed oral release or rectal administration. Further provided is a novel formulation for the oral administration of nicotine comprising a polyacrylic polymer complexed with nicotine.
Claims27
A therapeutic method of treating inflammatory bowel disease comprising locally administering to the rectum, colon and/or terminal ileum of a patient in need of such treatment, an amount of a complex of nicotine and a carbomer, effective to reduce the symptoms of said inflammatory bowel disease.
A complex of nicotine and a carbomer.
A rectally administrable pharmaceutical enema composition comprising an amount of a complex of nicotine and a carbomer together with a pharmaceutically acceptable carrier.
A post-gastric delayed release oral enterically coated capsule comprising a complex of nicotine and a carbomer.
A method of preparing a carbomer-nicotine complex comprising mixing carbomer with a pharmaceutically acceptable aqueous solvent;
- and adding nicotine to the carbomer-solvent mixture.
A therapeutic method of treating inflammatory bowel disease comprising administering to the rectum, colon and/or terminal ileum of a patient in need of such treatment an amount of a complex of nicotine and a carbomer and an amount of a compound selected from the group consisting of 5-amino salicylic acid, sulphasalazine, asalazine, prednisolone, and budesonide, said active agents being delivered in a therapeutic amount to reduce the symptoms of said inflammatory disease.
Dependencies are inferred from the claim text.